Wordt geladen...
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
BACKGROUND: Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been approved for treatment of metastatic melanomas with a BRAF p.V600E mutation. The clinical significance of non-codon 600 mutations remains unclear, in part, due to variation of kinase activ...
Bewaard in:
| Gepubliceerd in: | BMC Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4619530/ https://ncbi.nlm.nih.gov/pubmed/26498038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1811-y |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|